1. P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-α2 in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001). (6th September 2019) Authors: Gentner, B; Ciceri, F; DiMeco, F; Legnani, F; Eoli, M; Pollo, B; Farina, F; Mazzoleni, S; Russo, C; Naldini, L; Finocchiaro, G Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P14.57 WHO grade II and III meningioma: a large mono-institutional retrospective series. (9th September 2021) Authors: Simonetti, G; Gaviani, P; Farinotti, M; Legnani, F; Pollo, B; Pinzi, V; Botturi, A; Redaelli, V; Silvani, A Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P14.74 Grade II and III pleomorfic xanthoastrocitoma: a monocentric, retrospective analysis. (9th September 2021) Authors: Gaviani, P; Simonetti, G; Farinotti, M; Redaelli, V; Botturi, A; Pollo, B; Legnani, F; Pinzi, V; Silvani, A Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗